Abstract
Purpose: Despite advances in immunosuppressive therapy, T cell mediated rejection continues to be a significant source of morbidity and mortality in heart transplant patients past the first year. T cell antigen receptor (TCR) signaling is the essential element in these alloresponses against donor MHC and non-MHC antigens. Yet there is no therapy to specifically target this process. Dasatinib, an oral kinase inhibitor used for chronic myeloid leukemia, is exquisitely specific for Abl and Src family kinases (SFK), which are critical for the first step of T cell activation.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call